Sam Brusco, Associate Editor09.22.23
Abbott has completed the acquisition of Bigfoot Biomedical, a developer of smart insulin management systems for patient with diabetes.
The deal for Bigfoot was first announced in early September. Abbott and Bigfoot have collaborated on connected diabetes solutions since 2017.
The transaction expands Abbott’s presence in diabetes care. It builds on the company’s FreeStyle Libre portfolio on continuous glucose monitoring (CGM) technology and furthers the company’s aim in developing connected solutions to make diabetes management more personal and precise.
Bigfoot built Bigfoot Unity, a smart insulin management system that features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data with healthcare provider instructions to offer insulin dosing recommendations. The dosing recommendations are displayed on the pen cap's digital screen to help people know the amount of insulin to take.
Bigfoot’s Unity system exclusively works with Abbott's FreeStyle Libre tech and includes a customer smartphone app connected to a cloud-based online portal used by healthcare providers to support their patients, including remote care. The system works with FreeStyle Libre 2 sensors and all major brands of both basal and bolus disposable insulin pens offered in the U.S.
Upon completion of the deal, Bigfoot became a whole owned subsidiary of Abbott. Financial terms of the transaction were not disclosed.
The deal for Bigfoot was first announced in early September. Abbott and Bigfoot have collaborated on connected diabetes solutions since 2017.
The transaction expands Abbott’s presence in diabetes care. It builds on the company’s FreeStyle Libre portfolio on continuous glucose monitoring (CGM) technology and furthers the company’s aim in developing connected solutions to make diabetes management more personal and precise.
Bigfoot built Bigfoot Unity, a smart insulin management system that features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data with healthcare provider instructions to offer insulin dosing recommendations. The dosing recommendations are displayed on the pen cap's digital screen to help people know the amount of insulin to take.
Bigfoot’s Unity system exclusively works with Abbott's FreeStyle Libre tech and includes a customer smartphone app connected to a cloud-based online portal used by healthcare providers to support their patients, including remote care. The system works with FreeStyle Libre 2 sensors and all major brands of both basal and bolus disposable insulin pens offered in the U.S.
Upon completion of the deal, Bigfoot became a whole owned subsidiary of Abbott. Financial terms of the transaction were not disclosed.